Impact of the introduction of pneumococcal conjugate vaccine on immunization coverage among infants
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2431
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Impact of the introduction of pneumococcal conjugate vaccine on immunization coverage among infants ; volume:5 ; number:1 ; day:28 ; month:11 ; year:2005 ; pages:1-11 ; date:12.2005
BMC pediatrics ; 5, Heft 1 (28.11.2005), 1-11, 12.2005
- Contributor
-
Lin, Nancy D.
Kleinman, Ken
Chan, K Arnold
Yu, Xian-Jie
France, Eric K.
Xu, Stanley
Wei, Feifei
Mullooly, John
Santoli, Jeanne
Lieu, Tracy A.
SpringerLink (Online service)
- DOI
-
10.1186/1471-2431-5-43
- URN
-
urn:nbn:de:1111-201608139358
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:56 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Lin, Nancy D.
- Kleinman, Ken
- Chan, K Arnold
- Yu, Xian-Jie
- France, Eric K.
- Xu, Stanley
- Wei, Feifei
- Mullooly, John
- Santoli, Jeanne
- Lieu, Tracy A.
- SpringerLink (Online service)
Other Objects (12)
Nasopharyngeal Carriage in Children After the Introduction of Generalized Infant Pneumococcal Conjugate Vaccine Immunization in Germany
Pneumococcal conjugate vaccine implementation in middle-income countries
Estimating the Public Health and Economic Impact of Introducing the 13-Valent Pneumococcal Conjugate Vaccine or 10-Valent Pneumococcal Conjugate Vaccines into State Immunization Programs in India
Pneumococcal conjugate vaccination schedules in infants—acquisition, immunogenicity, and pneumococcal conjugate and yellow fever vaccine co-administration study
Correction to: Estimating the Public Health and Economic Impact of Introducing the 13-Valent Pneumococcal Conjugate Vaccine or 10-Valent Pneumococcal Conjugate Vaccines into State Immunization Programs in India
Dynamic models of pneumococcal carriage and the impact of the Heptavalent Pneumococcal Conjugate Vaccine on invasive pneumococcal disease
Effect of pneumococcal conjugate vaccine six years post-introduction on pneumococcal carriage in Ulaanbaatar, Mongolia
Cost-Effectiveness of 20-Valent Pneumococcal Conjugate Vaccine in Argentinean Adults
Pneumococcal conjugate vaccination schedules in infants—acquisition, immunogenicity, and pneumococcal conjugate and yellow fever vaccine co-administration study: statistical analysis plan
Pneumococcal Conjugate Vaccine Impact on Serotype 3: A Review of Surveillance Data
Cost-effectiveness of 20-valent pneumococcal conjugate vaccine compared with 23-valent pneumococcal polysaccharide vaccine among adults in a Norwegian setting
The potential role of pneumococcal conjugate vaccine in reducing acute respiratory inflammation in community-acquired pneumococcal pneumonia
Nasopharyngeal Carriage in Children After the Introduction of Generalized Infant Pneumococcal Conjugate Vaccine Immunization in Germany
Pneumococcal conjugate vaccine implementation in middle-income countries
Estimating the Public Health and Economic Impact of Introducing the 13-Valent Pneumococcal Conjugate Vaccine or 10-Valent Pneumococcal Conjugate Vaccines into State Immunization Programs in India
Pneumococcal conjugate vaccination schedules in infants—acquisition, immunogenicity, and pneumococcal conjugate and yellow fever vaccine co-administration study
Correction to: Estimating the Public Health and Economic Impact of Introducing the 13-Valent Pneumococcal Conjugate Vaccine or 10-Valent Pneumococcal Conjugate Vaccines into State Immunization Programs in India
Dynamic models of pneumococcal carriage and the impact of the Heptavalent Pneumococcal Conjugate Vaccine on invasive pneumococcal disease
Effect of pneumococcal conjugate vaccine six years post-introduction on pneumococcal carriage in Ulaanbaatar, Mongolia
Cost-Effectiveness of 20-Valent Pneumococcal Conjugate Vaccine in Argentinean Adults
Pneumococcal conjugate vaccination schedules in infants—acquisition, immunogenicity, and pneumococcal conjugate and yellow fever vaccine co-administration study: statistical analysis plan
Pneumococcal Conjugate Vaccine Impact on Serotype 3: A Review of Surveillance Data
Cost-effectiveness of 20-valent pneumococcal conjugate vaccine compared with 23-valent pneumococcal polysaccharide vaccine among adults in a Norwegian setting
The potential role of pneumococcal conjugate vaccine in reducing acute respiratory inflammation in community-acquired pneumococcal pneumonia
Nasopharyngeal Carriage in Children After the Introduction of Generalized Infant Pneumococcal Conjugate Vaccine Immunization in Germany
Pneumococcal conjugate vaccine implementation in middle-income countries
Estimating the Public Health and Economic Impact of Introducing the 13-Valent Pneumococcal Conjugate Vaccine or 10-Valent Pneumococcal Conjugate Vaccines into State Immunization Programs in India
Pneumococcal conjugate vaccination schedules in infants—acquisition, immunogenicity, and pneumococcal conjugate and yellow fever vaccine co-administration study
Correction to: Estimating the Public Health and Economic Impact of Introducing the 13-Valent Pneumococcal Conjugate Vaccine or 10-Valent Pneumococcal Conjugate Vaccines into State Immunization Programs in India
Dynamic models of pneumococcal carriage and the impact of the Heptavalent Pneumococcal Conjugate Vaccine on invasive pneumococcal disease
Effect of pneumococcal conjugate vaccine six years post-introduction on pneumococcal carriage in Ulaanbaatar, Mongolia
Cost-Effectiveness of 20-Valent Pneumococcal Conjugate Vaccine in Argentinean Adults
Pneumococcal conjugate vaccination schedules in infants—acquisition, immunogenicity, and pneumococcal conjugate and yellow fever vaccine co-administration study: statistical analysis plan
Pneumococcal Conjugate Vaccine Impact on Serotype 3: A Review of Surveillance Data
Cost-effectiveness of 20-valent pneumococcal conjugate vaccine compared with 23-valent pneumococcal polysaccharide vaccine among adults in a Norwegian setting